Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Depreciation & Amortization (CF) (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 4.97% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.4 million through Dec 2025, down 10.55% year-over-year, with the annual reading at $5.4 million for FY2025, 10.55% down from the prior year.
  • Depreciation & Amortization (CF) hit $1.4 million in Q4 2025 for BridgeBio Pharma, up from $1.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $3.5 million in Q2 2021 to a low of $265000.0 in Q3 2021.
  • Historically, Depreciation & Amortization (CF) has averaged $1.5 million across 5 years, with a median of $1.6 million in 2022.
  • Biggest YoY gain for Depreciation & Amortization (CF) was 520.75% in 2022; the steepest drop was 54.62% in 2022.
  • Year by year, Depreciation & Amortization (CF) stood at $1.5 million in 2021, then grew by 8.78% to $1.7 million in 2022, then dropped by 4.52% to $1.6 million in 2023, then fell by 13.75% to $1.4 million in 2024, then increased by 4.97% to $1.4 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for BBIO at $1.4 million in Q4 2025, $1.4 million in Q3 2025, and $1.3 million in Q2 2025.